Enzyme News and Research

RSS

Phycobilins found to inhibit SARS-CoV-2 enzymes in vitro

Researchers have released an interesting new study that describes the broad-spectrum of antiviral activity that phycobilins can have. Phycobilins, which are bioactive plant compounds, were found to inhibit two coronavirus enzymes.

26 Nov 2020

Early interferon therapy may mitigate COVID-19 severity

A recent review of COVID-19 therapies explores the utility of interferons in the battle against severe COVID-19, and concludes that they deserve further development.

26 Nov 2020

Researchers elucidate the action mechanism of incretin-based drugs in treatment of diabetes

An international research group has clarified the action mechanism of incretin-based drugs in the treatment of diabetes.

26 Nov 2020

Mystery behind an enigmatic organelle solved

Carbon is one of the main building blocks for life on Earth. It's abundant in our planet's atmosphere, where it's found in the form of carbon dioxide.

25 Nov 2020

Researchers discover close SARS-CoV-2-relative in animal hosts outside China

In a major new discovery that might deepen our understanding of SARS-CoV-2’s animal origins and its genetic evolution, coronaviruses very closely related to SARS-CoV-2 have been discovered in two horseshoe bats outside of China.

25 Nov 2020

UB researchers uncover new functions in ataxin 3 gene that causes Machado-Joseph disease

Ataxia is a minority disease with genetic origins, known for its neuromuscular alterations due to the selective loss of neurons in the cerebellum, the organ of our nervous systems which controls movement and balance.

25 Nov 2020

Researchers describe important cause of fatal influenza

It is largely unknown why influenza infections lead to an increased risk of bacterial pneumonia. Researchers at Karolinska Institutet in Sweden have now described important findings leading to so-called superinfections, which claim many lives around the world every year.

25 Nov 2020

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Researchers report SARS-CoV-2 antibodies to the spike protein (S protein) can persist 200 days after symptom onset, but that antibodies to the nucleoprotein (N protein) can reduce much more rapidly.

25 Nov 2020

Is COVID-19 severity mediated by higher antibody response?

A new study indicates that patients with more severe COVID-19 have a stronger antibody response.

25 Nov 2020

Study reveals a gene responsible for anthraquinone synthesis in plants

Anthraquinones are a class of naturally occurring compounds prized for their medicinal properties, as well as for other applications, including ecologically friendly dyes.

25 Nov 2020

Mefloquine shows potential as anti-SARS-CoV-2 drug

A team of scientists from Japan has identified the approved anti-material drug, mefloquine, as a potential candidate to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Specifically, mefloquine has been shown to prevent the entry of SARS-CoV-2 into host cells and reduce the viral load in vitro.

24 Nov 2020

Scientists show SARS-CoV-2's viral replication with 3D integrative imaging

A team of researchers at Heidelberg University in Germany have performed a detailed imaging analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to determine how the virus reprograms infected cells.

24 Nov 2020

Aprotinin inhibits SARS-CoV-2 entry and replication in cells cultures

Researchers at the University of Kent in the UK and the Hannover Medical School and Goethe University in Germany have observed that the protease inhibitor aprotinin can inhibit viral replication by preventing SARS-CoV-2 entry into host cells.

24 Nov 2020

Researchers recommend antibody cocktail to tackle SARS-CoV-2 mutations

A new study released on the medRxiv* preprint server indicates that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic – is developing multiple mutations that affect neutralization by antibodies.

24 Nov 2020

Biosensor assay SARS-CoV-2 antibody test may predict COVID-19 severity in patients

Researchers in New York, USA, have found an association of mortality with an early humoral response to SARS-CoV-2 infection within the first few days after onset of symptoms (DAOS), using a highly sensitive and automated testing-on-a-probe (TOP) biosensor assays for SARS-CoV-2.

24 Nov 2020

SARS-CoV-2's spike protein mutations have slowed, study finds

A team of researchers at the School of Information Sciences in Illinois, USA, has revealed the rate of mutation in the 29 proteins that make up the SARS-CoV-2 microbe.

23 Nov 2020

Novel targeted therapy blocks metabolic pathways in cancer cells with specific genetic defects

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical metabolic pathways in cancer cells with specific genetic defects.

23 Nov 2020

Scientists make breakthrough in studying the enzyme involved in fish odor syndrome

Fish odor syndrome (trimethylaminuria) is a debilitating disease, in which the liver cannot break down the smelly chemical trimethylamine which is produced by enzymes from bacteria residing in the gut leaving people with a fish like odor.

23 Nov 2020

Nasal dryness could be an early warning sign of COVID-19

A new study published by an international team of researchers on the preprint medRxiv* server in November 2020 details the nasal symptoms that are associated with anosmia and ageusia (loss of smell and taste) in coronavirus disease 2019 (COVID-19), including the early warning signs of infection.

23 Nov 2020

Modified SARS-CoV-2 receptor-binding domain could increase vaccine efficacy, says study

A team of researchers from the USA and China have engineered a receptor-binding domain (RBD) that they claim improves the immunogenicity of multivalent SARS-CoV-2 vaccines. Their study, which was released on the bioRxiv* in November 2020, may help advance even more efficacious SARS-CoV-2 vaccine candidates in the future.

23 Nov 2020